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Global biosecurity threats such as the spread of emerging infectious diseases (i.e.,
avian influenza, SARS, Hendra, Nipah, etc.) and bioterrorism have generated
significant interest in recent years. There is considerable effort directed towards
understanding and negating the proliferation of infectious diseases. Biosensors
are an attractive tool which have the potential to detect the outbreak of a virus
and/or disease. Although there is a host of technologies available, either
commercially or in the scientific literature, the development of biosensors for the
detection of emerging infectious diseases (EIDs) is still in its infancy. There is no
doubt that the glucose biosensor, the gene chip, the protein chip, etc. have all
played and are still playing a significant role in monitoring various biomolecules.
Can biosensors play an important role for the detection of emerging infectious
diseases? What does the future hold and which biosensor technology platform is
suitable for the real-time detection of infectious diseases? These and many other
questions will be addressed in this review. The purpose of this review is to present
an overview of biosensors particularly in relation to EIDs. It provides a synopsis of
the various types of biosensor technologies that have been used to detect EIDs,
and describes some of the technologies behind them in terms of transduction and
bioreceptor principles.
1 Introduction
There is great deal of interest in moni-
toring and controlling the spread of
emerging infectious diseases (EID) in the
international community.1–7 EIDs can be
broadly classified as: (a) new, previously
unrecognised diseases (e.g., severe acute
respiratory syndrome); (b) known dis-
eases which have increased in incidence,
virulence or geographic range over the
past several decades (e.g., foot-and-mouth
disease); and (c) diseases which threaten
to increase in the near future (e.g., avian
influenza).8 A complex interplay of fac-
tors such as greater global movement of
people and animals, demographic shifts,
ecological changes, climate changes,
changes in animal husbandry practices,
etc. have led to the emergence of an
increasing number of new diseases.9,10
Clearly, there are many challenges facing
organizations and nations concerned with
controlling the proliferation of EIDs.
Disease surveillance and diagnosis are
integral and crucial components of all
public health services. An adequate detec-
tion system is an essential step in helping
to eliminate or minimize the spread of a
virus outbreak before the economic,
human, and environmental repercussions
become devastating.
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Because of the threat posed by EIDs,
the speedy detection of a virus or antigen
has a major impact on the success of
strategies for disease zoning, control or
eradication. Disease surveillance and
detection strategies come in various
shapes and forms ranging from syndro-
mic to remote sensing.1 The intention of
surveillance is to improve data collection
and management, and provide improved
decision-making tools. Early warning
systems are crucial for disease emergency
vigilance. The collection of data and
diagnostic specimens particularly from
free-living populations of animals can be
at times difficult to achieve because of
the vast size of territories, the sparse
human population, and lack of physical
infrastructure. More importantly, the
problem with existing surveillance pro-
grams is the long time delay between
sample collection in remote areas and
transportation to laboratories, which can
be a significant distance away from the
site of collection. Depending on the type
of EID and the weather conditions, it
may only take several hours for the
disease to spread through an animal
and/or human population. Searching for
a rapid, simple and sensitive method is of
considerable interest. One of the pro-
blems with EID detection is actually
determining whether infection has
occurred. The difficulty arises because
the initial symptoms after infection can
be difficult to distinguish from other
infections. Consequently, there is a need
to develop rapid and reliable tools/
systems for the detection of EIDs in the
community. One attractive tool that is
capable of providing immediate informa-
tion on a disease outbreak is the biosen-
sor. It is well established that biosensors
play a significant role in medicine/clinical
analysis,11–13 food/water analysis,14–16
environmental monitoring,17,18 and agri-
culture.19,20 In principle, biosensors offer
the possibility of real-time monitoring,
and the deployment of these devices in
the field would provide a means for rapid
virus detection. An ideal disease detec-
tion and surveillance system would
involve various processes as shown in
Fig. 1.
Generally, biosensors are distinguished
from one another by the nature of the
process and according to their biochemical
or biological component, e.g., biocatalytic
(i.e., enzyme), immunological (i.e., anti-
body) and nucleic acid (i.e., DNA). A
number of biosensors have been developed
for EIDs; however, all of them essentially
comprise a biological recognition element
or bioreceptor, which interacts with the
analyte and responds in some manner that
can be detected by a transducer (refer to
Fig. 2). The biological recognition element
or bioreceptor is a crucial component and
its function is to impart selectivity so that
the sensor responds only to a particular
analyte or biomolecule of interest, hence
avoiding interferences from other sub-
stances. The transducer is the other
component of the biosensor, which also
plays an important role in terms of
converting the biorecognition event into
an electrical signal, and common transdu-
cers employed for EID detection include
electrochemical, optical, and piezoelectric
platforms. An ideal biosensor is one that is
reagentless; however, in most studies
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Fig. 1 An ideal approach to real-time disease detection and surveillance.
Fig. 2 A schematic diagram of a typical biorecognition element.
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reported in the literature a co-substrate is
normally used. The addition of an enzyme,
redox species, etc. is mainly designed to
help with the transduction process by
facilitating the generation of a detectable
product. In fact, detection strategies can
be divided into two categories: nonlabeled
or label-free types, which are based on the
direct measurement of a phenomena
occurring during the biochemical reac-
tions on a transducer surface; and labeled,
which relies on the detection of a specific
label. Research into ‘label-free’ biosensors
continues to grow;21–23 however ‘labeled’
ones are more common and are extremely
successful in a multitude of platforms.
Since well over 6000 articles have been
published in the area of biosensors just
from the years 1996 to 2006 alone
(English journals), this manuscript is
not meant to be a comprehensive review
of the field, but rather a critical review,
presenting a selection of the most sig-
nificant technologies and advances in
relation to EID monitoring. One of the
major challenges when reviewing the
literature is the unclear distinction
between a biosensor and a bioanalytical
instrument. The term ‘biosensor’ has
been loosely applied in the literature,
noting that on many occasions it has
been used to describe an analytical device
that incorporates several additional
separation steps, which is independent
from detection.§ It is not the intention of
this review to critically evaluate the
various types of biosensors nor will it
present a summary of recommendations
for effective biosensing. Rather, the
objective of this review is to address the
development of biosensors for the detec-
tion of EIDs. In addition, it will discuss
some recent biosensor advances and
problems that need to be resolved before
they make the journey into the market
place. The emphasis will be on the
development towards hand-held/implan-
table analytical devices rather than
laboratory instruments. This review cov-
ers papers that have been published over
the last decade on EID detection and has
been structured into four main sections:
electrochemical biosensors, optical bio-




Table 1 summarises the main analytical
features of a wide range of biosensors,
noting that a majority of the existing
technologies used for detecting EIDs rely
on antibodies as the recognition mole-
cule. Antibodies are the critical part of an
immunosensor, since their quality con-
tributes to the sensitivity and specifi-
city.25 As it is beyond the scope of this
review, the reader is referred to other
articles for a more detailed description of
immunosensors.11,26,27 An outline of the
key immunological procedures employed
for the identification of EIDs can be
found in the review by Peruski and
Peruski.28 However, it is important to
note that the success of an immunosensor
depends heavily on which antibodies,
labels, and reagents are used in the
assay.28,29" Once antibodies of the
desired specificity and affinity have
been developed, they can be incorporated
in a wide range of transducer platforms.
DNA is an alternative recognition
§ According to IUPAC recommendations, a
biosensor is ‘‘a self-contained integrated
receptor–transducer device, which is capable
of providing selective quantitative or semi-
quantitative analytical information using a
biological recognition element’’.24
" One of the major challenges with detecting
EIDs is the availability of specific antibodies,
and a great deal of effort has been undertaken
in generating acceptable receptors/reagents.
Table 1 A summary of selected biosensors used for the detection of EIDs
Transducer Analyte Biosensor format Detection limit Ref.
Amperometric Newcastle disease Enzyme-label immunoassay 11.1 ng ml21 45
Forest–Spring encephalitis Sandwich gold-label immunoassay 1027 mg ml21 46
Japanese B encephalitis Fe2+/3+ probe & label-free immunoassay 6 6 1029 1g pfu ml21 47
Hepatitis B Methylene blue probe, PCR & DNA NA 48
Hepatitis B Osmium complex probe, PCR & DNA NA 49
Potentiometric Hepatitis B Enzyme label immunoassay y50 fM 51
Japanese B encephalitis Immunoassay 6 6 1029 1g pfu ml21 52
Light-addressable
potentiometric
Newcastle disease Sandwich enzyme-label immunoassay 2 ng ml21 53, 54
Venezuelan equine
encephalitis
Sandwich enzyme-label immunoassay 30 ng ml21 56
Impedance spectroscopy Hepatitis B Immunoassay 8 ng ml21 60
Hepatitis B Immunoassay 50 ng l21 61
Conductometric Bovine viral diarrhoea Sandwich immunoassay Varied between
102–104 CCID ml21
68, 69
Fiber-optic evanescent wave Newcastle disease Fluorescein-label sandwich immunoassay 10 ng ml21 93
Surface plasmon resonance Foot-and-mouth disease Immunoassay NA 98–100
Hepatitis A Immunoassay NA 101
Severe acute respiratory
syndrome
Peptide binding NA 102
Fluorescence Various toxins Immunoassay yng ml21 109, 110
Dengue Immunoassay NA 111
Dengue Nucleic acid yPicomolar 112, 113
Piezoelectric Foot-and-mouth disease Immunoassay NA 115
Foot-and-mouth disease Immunoassay NA 116
Hepatitis B Nucleic acid y0.01 mg ml21 117
Severe acute respiratory
syndrome
Immunoassay 0.6 mg ml21 118
Dengue Immunoassay ymg ml21 119–121
a NA = not available.
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molecule that has also received some
attention for the detection of EIDs. A
number of excellent reviews have been
published elsewhere on sensors based on
nucleic acid interaction, noting that the
detection of specific DNA sequences
provides the fundamental basis for mon-
itoring a wide variety of genetic diseases
and viral infections.30–36 Despite the
great deal of work in this area the
application of a DNA biosensor for
EID detection is still in its infancy.
One of the major requirements in
developing a biosensor for EIDs is the
need for a sensitive analytical device that
can easily go down to very low detection
levels without significant changes in
selectivity. Many infectious diseases will
spread rapidly through a community
before any symptoms are identified1
and a biosensor that can easily detect
low levels of antigen at the onset of
infection will be invaluable. In addition,
a biosensor that is relatively cheap,
robust, responds rapidly and provides
high-throughput is highly desired for
field applications. However, the type of
biosensor used for EIDs will in many
cases depend on the properties of the
analyte (i.e., size, structure, concentra-
tion, etc.) and the matrix (i.e., air, liquid)
in which the analyte is found. In fact, the
sensitivity of the biosensor is highly
dependent on the surface preparation/
structure and a great deal of effort has
been focussed on understanding and
tailoring the interfacial properties.37,38I
The most commonly used biosensing
methodologies for detecting EIDs will
be described in detail.
2.1 Electrochemical biosensors
More than half of the biosensors used for
the detection of pathogens and viruses
are based on electrochemical transdu-
cers.39 Furthermore, a number of reports
have demonstrated the importance of
electrochemical biosensors in clinical
and environmental analysis26,27,40,41
This may not be surprising considering
that electrochemical transduction pos-
sesses the following advantages: low cost;
high sensitivity; independence from solu-
tion turbidity; easily miniaturized/well
suited to microfabrication; low power
requirements; and relatively simple
instrumentation.42 These characteristics
make electrochemical detection methods
highly attractive for field monitoring of
infectious diseases and biological warfare
agents. Several electrochemical
approaches (i.e., amperometric, potentio-
metric, impedance) have been used to
monitor the changes that occur during
EID detection. The method used in many
cases depends on the type of change (i.e.,
redox, ionic, conductivity, etc.) along
with the properties of the analyte and
matrix. For instance, biosensors that
involve amperometric detection usually
employ an electroactive marker, noting
that the antibody–antigen and DNA
hybridization reactions do not generate
a significant signal on their own. For a
discussion of the electron transfer
mechanisms that commonly occur with
amperometric-based biosensors, we refer
readers to the review by Habermuller
et al.43 However, the relative merits of
each electrochemical transducer will be
explored in terms of EID detection
requirements.
Without a doubt the amperometric
sensor for glucose is one of the most
studied and successful of all biosensors.44
This has led to the development of a vast
array of immunosensors and DNA bio-
sensors that are based on this form of
detection. Indeed, the amperometric
approach has become a popular choice
for the detection of EIDs and biological
warfare agents. Recently, Yu and co-
workers45 developed an amperometric
immunosensor for the assay of
Newcastle disease in citrate buffer solu-
tions. The Newcastle disease antigen was
immobilized onto a graphite paste
matrix, which was prepared according
to two different methods. An enzyme
labeled (i.e., horseradish peroxidase)
antibody was used to catalyze the oxida-
tion of hydrogen peroxide on a tetra-
methylbenzidine substrate thereby
generating a current response that was
directly related to the virus concentra-
tion. It was shown that the sensor
response depends on the Newcastle dis-
ease antigen loading, immunosensor
preparation conditions, tetramethylben-
zidine concentration, and incubation
time. Similarly, work by Brainina et al.46
revealed that amperometric detection is
an effective and sensitive approach for
the diagnosis of Forest–Spring encepha-
litis. Detection was achieved using a
sandwich approach, which involved
immobilizing the antigen onto a graphite
electrode followed by binding with anti-
body and a gold-labeled protein A. The
sensor was shown to respond to Forest–
Spring encephalitis virus over a wide
concentration range (i.e., 1027 to 1022
mg ml21). More importantly, the analy-
sis was carried out in real blood serum
samples and the analytical results were in
excellent agreement compared to the
standard ELISA method.46 In many
cases, detection with amperometric bio-
sensors is achieved by using an enzyme
label in order to improve the sensitivity.
However, the group of Yuan47 developed
a label-free amperometric immunosensor
for Japanese B encephalitis vaccine. The
immunosensor was fabricated by immo-
bilizing the antiserum of Japanese B
encephalitis on a gold nanoparticle/
o-phenylenediamine polymer layer that
was deposited onto a Prussian blue
coated platinum electrode.47 The
response was evaluated as a function of
Japanese B encephalitis vaccine concen-
tration, temperature, pH, incubation
time, and gold nanoparticle–polymer
layer thickness. It was reported that the
immunosensor responded to Japanese B
encephalitis vaccine in the concentration
range 1.1 6 1028 to 1.9 6 1026 plaque
forming unit ml21.47 It is evident that the
above biosensor studies are based on
immunoassay principles; however, there
also appears to be some interest in the
development of amperometric sensors for
DNA detection. Various groups have
shown that this approach is particularly
suitable for the detection of Hepatitis B
virus, noting that a polymerase chain
reaction step was also incorporated in the
assay.48,49 Despite the analytical success,
the main drawback in using DNA
biosensors for EID detection is the long
assay times (y4 h) and the difficulty in
establishing if a particular disease is
infectious. To add further complications,
this genetic material is packaged inside
an envelope and the quantity is usually
very small and not very stable.
The development of potentiometric
sensors for the detection of EIDs has
also received a great deal of attention.
This group of sensors are known to have
the longest history and the largest
number of applications.50 However, most
I Controlling the surface chemistry and cov-
erage is paramount in ensuring high reactivity,
stability, orientation and accessibility as well
as minimizing non-specific binding processes.
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of the work reported in the literature
using potentiometric-sensing principles
employs the indirect approach for the
detection of virus and biological warfare
agents. This involves measuring a change
in either the pH, redox potential or
changes in the ionic concentration of an
elemental species, which occur during a
biorecognition event. A common strat-
egy that has been employed is the use of
enzymes to catalyze the consumption or
production of protons and/or charged
elemental species. The approach devel-
oped by Purvis and coworkers51 involved
the formation of an enzyme labeled (i.e.,
horseradish peroxidase) immuno-com-
plex at the surface of a polypyrrole-
coated gold electrode. The detection of
Hepatitis B virus in blood/serum was
achieved by a secondary reaction that
produced charged products (i.e., changes
in the redox state, pH and/or ionic
strength), and the potential shift was
measured with respect to a silver/silver
chloride reference electrode.51 Further-
more, a comparative study was under-
taken and the results agreed favourably
with the standard ELISA method.
Reports suggest that the potentiometric-
based immunosensor is rapid (,15 min),
stable (i.e., 4 months), reproducible
(CV ,5% at 0.1 ng ml21), and sensitive
(y50 fM).51 Others have shown that a
potentiometric immunosensor based on a
modified platinum electrode can be used
to detect Japanese B encephalitis anti-
gen.52 Zhang et al.52 coated the platinum
electrode with a colloidal gold nanopar-
ticle/conductive polymer film followed by
the immobilization of the Japanese B
encephalitis antibody.52 The shift in
potential was related to the antigen
concentration in solution, and the poten-
tiometric response mechanism was
explained in terms of a change in the
density of electron charges. Despite the
promising analytical results of the poten-
tiometric biosensor, further work still
needs to be undertaken in order to clarify
the response mechanism in blood.**
Some reports suggest that potentio-
metric transducers cannot provide the
required sensitivity for the detection of
antibody–antigen reactions.26 However,
a light addressable potentiometric sensor
(LAPS) based on a field effect transistor
(FET) technology has proved to be
highly successful for the immunoassay
of various viruses and pathogens. A
LAPS device consists of n-type silicon
doped with phosphorus and an insulating
layer in contact with the aqueous solu-
tion. An alternating photocurrent is
generated when a light source flashes
rapidly, such as a light emitting diode
(LED), and the FET is used to detect
changes in the potential at the silicon-
insulator surface. The group of Lee53,54
developed a LAPS biosensor to detect
Newcastle disease virus, and it was
shown that the sensor responds linearly
to the virus over a wide concentration
range. The assay procedure involved a
filtration capture step in which the
sandwich immuno-complex was passed
through a biotin-embedded nitrocellulose
membrane and immobilized onto the
membrane via the biotin-streptavidin
interaction. An enzyme-immunoassay
LAPS approach was also used by
Uithoven et al.55 who showed that the
potentiometric detection platform can
rapidly monitor (,15 min) biological
warfare (BW) agents in the field. In this
process, a BW agent forms an immuno-
complex with both a fluorescein-labelled
antibody and a biotin-streptavidin-
labelled antibody.55 The fluorescein-
labelled immunocomplex undergoes a
further complexation reaction with an
anti-fluorescein urease conjugated anti-
body, and the enzymatic breakdown of
urea causes a change in pH, which is
detected potentiometrically.55 More
importantly, the biosensor employs an
eight-channel instrument, which can
assay up to eight BW agents simulta-
neously.55 Others have used LAPS to
identify the virus Venezuelan equine
encephalitis in cultured cells.56 In this
study, an immunofiltration enzyme
assay was used in conjunction with the
LAPS device, and a limit of detection of
y30 ng ml21 was achieved.56
Impedance spectroscopy is another
electrochemical method that has also
received some interest for the detection
of EIDs. It is well known that during a
biorecognition event several physico-
chemical processes (i.e., changes in the
electric double layer and charge transfer)
transpire at and near the surface of a
biosensor, and by applying a controlled
AC electrical stimulus over a selected
range of frequencies the variations in the
sensor surface properties (i.e., interfacial
capacitance, charge transfer resistance)
can be linked to the biochemical changes,
and the reader is referred to several
fundamental reviews which have been
published recently on the topic.57–59 An
interesting trend that has started to
emerge is the development and applica-
tion of EIS for the detection of viruses.{{
Indeed, the group of Yuan60 used it to
detect hepatitis B antigen by observing a
change in the electron transfer resistance
of a redox probe before and after
antigen–antibody interaction. The hepa-
titis B antibody was immobilized onto a
platinum electrode modified with colloi-
dal gold and polyvinyl butyral. EIS
measurements were performed at an
electrode potential of +220 mV and it
was demonstrated that the sensor
responds linearly to the hepatitis B
antigen over the concentration range of
20–160 ng ml21, and a limit of detection
of 8 ng ml21 was obtained.60 However,
Wang et al.61 were able to improve the
detection limit for hepatitis B virus (i.e.,
50 ng l21) and extend the linear analy-
tical range (i.e., 0.5–200 mg l21) by also
using colloidal gold nanoparticles. The
immunosensor was fabricated by form-
ing a combined self-assembled mono-
layer of 4-aminothiophenol and colloidal
gold nanoparticles. The impedance-based
sensor was optimized by investigating the
effect of various surface layers, incuba-
tion time, and antigen concentration on
the response mechanism. It was revealed
that the electron transfer resistance
increases with elevated antigen concen-
trations. Unfortunately, no explanation
was provided by the authors on the
mechanism responsible for the observed
change in impedance.
Many of the studies reported in the




with detection. It is evident that EIS is
a powerful detection method in clean
buffered solutions;57–59 however, it
remains to be seen if this method works
well for monitoring EIDs in a complex
matrix such as blood. Signals arising
** There is no doubt that the potentiometric
methods are highly sensitive to changes in the
chemistry and ionic properties of blood and
this could severely limit their application for
real-time monitoring of EIDs.
{{ An important feature of EIS is that it is
able to provide ‘reagentless’ or ‘label-free’
sensing,62,63 and this makes it highly attractive
for real-time monitoring.
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from non-specific adsorption processes
are still a problem and a great deal of
effort has been devoted to controlling the
surface structure.64 Similarly, a number
of challenges still exist in relation to
sensitivity, and further work needs to be
done in this area before this technology
can play a future role in the real-time
detection of EID. Recent work by the
group of Higson and coworkers65 has
demonstrated that the fabrication of a
microelectrode array may help improve
the sensitivity and it will be interesting to
see if this approach works for EIDs.
There has been a great deal of effort
to understand the relationship between
conductivity and antibody–antigen inter-
action. Subsequently, conductometric-
based biosensors have been used to
measure the changes in conductance
before and after a biorecognition event,
noting that during a biorecognition event
the ionic concentration/composition
changes and this leads to a change in
the solution electrical conductivity. Early
reports suggested that the sensitivity of
this technique is generally inferior com-
pared to other electrochemical methods;
however, recent studies have shown that
it is capable of rapidly detecting
(,10 min) various food borne pathogens
down to very low levels.66,67 The group
of Alocilja68,69 showed that this
approach can be extended and used to
detect bovine viral diarrhoea virus
(BVDV) over a wide concentration
range. The biosensor was fabricated
using a conductive polyaniline label in
the sandwich immunoassay scheme, and
it was demonstrated that polyaniline
improves the sensitivity of the biosensor
by forming a conductive molecular
bridge between the two electrodes.
More importantly, it was shown that
the sensor can be used to detect BVDV in
artificial blood serum samples.68
Regrettably, the authors have failed to
validate their BVDV biosensor against a
standard immunoassay method. There is
no doubt that the conductometric bio-
sensor platform is a sensitive technique;
however, biosensor validation studies
still need to be performed before it is
routinely used for the detection of EIDs.
Gold and carbon are the most com-
mon materials used to carry current/
charge during an electrochemical
event.43,70 Similarly, there has been con-
siderable interest in the development of
biosensors that use conductive polymers
(e.g. polyaniline, polypyrrole) as an
electrochemical transducer.66,71,72 The
growth in the use of conductive polymers
has primarily been stimulated by
improved response characteristics such
as increased sensitivity, stability, and
reproducibility. It is well known that
the response of polymer-based sensors is
greatly dependent on the mode of poly-
merization, the monomer concentration,
and the counterions used during poly-
merization.51,73 By varying these para-
meters, it allows the surface properties
of the biosensor to be modified, and
this feature can be exploited in order
to optimize the transduction signal.
Likewise, the development of nanoma-
terials as electrodes for electrochemical-
based detectors represents an exciting
area of research. The growth in nanoma-
terials has the potential to revolutionize
new developments in EID detection. The
ability of carbon nanotubes to promote
electron-transfer reactions is well docu-
mented.74,75 Electrodes modified with
carbon-nanotubes have been recently
reported by Wang and coworkers for
monitoring various biomolecules.76–78
Although they have shown promising
results in DNA- and enzyme-based bio-
sensors,76–79 little work has been done
using carbon-nanotubes for monitoring
EIDs. Obviously, the next step that needs
to be taken is to see how these materials
perform for the detection of EIDs,
particularly in a complex matrix such as
blood.
Electrochemical sensors offer many
opportunities for the detection of EIDs.
In particular, the amperometric-based
biosensor appears to be showing promis-
ing signs in terms of sensitivity and
selectivity compared to other electroche-
mical methods. Despite the remarkable
sensitivity, rapid response, miniaturiza-
tion capability, and low cost there are
still problems with long-term stability
and selectivity in blood. In fact, many of
the amperometric biosensor studies
involving EID detection have been
undertaken in well-defined buffer solu-
tions, and it is not known if this
technology is selective enough to detect
EIDs directly in blood. Obviously,
further work would be required to
demonstrate that the electrochemical
biosensors do not suffer from biofouling
problems. Such problems can be partly
addressed by covering the transducer or
sensor surface with an appropriate selec-
tive film that rejects undesirable compo-
nents.80 However, this approach may
not work very well when analyzing
large molecules (i.e., viruses), which
need to diffuse through the selective
layer to reach the sensor surface.
Notwithstanding, the use of disposable
screen printed electrodes appears to be a
realistic strategy for EID detection.{{
Consequently, screen printed electrodes
have attracted a great deal of attention
recently as a platform in DNA, immuno
and enzyme-based biosensors.51,72,77,81–87
The technology is particularly attractive
for the mass production of cheap dis-
posable electrodes. On the other hand,
this strategy may be somewhat limited to
applications that do not require long-
term real-time monitoring.
2.2 Optical biosensors
When light (usually monochromatic) is
passed through a sample, several things
can transpire. The light can either be
reflected back or it can be transmitted
through the sample. The process that
occurs will depend on the wavelength of
light, the angle of incidence, the sample
composition (i.e., the type and concen-
tration of molecules, etc.) and sample
thickness. By exploiting the energy from
the electromagnetic spectrum it can be
used to provide information about the
changes in the local environment sur-
rounding the analyte. Optical biosensors,
which are sometimes referred to as
‘optodes’, have received considerable
interest on the detection of viruses and/
or pathogens.88 Various modes of optical
measurement exist (i.e., absorption;
reflection; fluorescence; chemilumines-
cence; and phosphorescence);89 however,
biosensors based on surface plasmon
resonance and fluorescence principles
are the most common and promising
methods for EID detection. Similarly,
recent progress in fiber-optic technology
suggests that optical biosensors may
become a powerful tool in the imminent
future for the real-time and remote
detection of EIDs.90–92 In practice, fiber
{{ It is well known that ‘memory effects’ and/
or ‘membrane fouling’, which is sometimes
observed with electrochemical-based biosen-
sors, can be alleviated when using disposable
screen printed electrode sensors.
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optics can be coupled with all optical
techniques, thus increasing their versati-
lity. A number of articles have appeared
in the literature reviewing the use of
optical fibers,90–92 and it was concluded
that the detection limits of optical fiber-
based biosensors are comparable to
sophisticated large bench-top instru-
ments. Lee and Thompson93 were able
to detect the Newcastle disease (ND)
virus down to 10 ng ml21 using a fiber-
optic evanescent wave biosensor. A
polyclonal antibody was immobilized
covalently onto an aminosilane-coated
quartz fiber, and detection was achieved
using fluorescein-labelled anti-ND in a
sandwich format.93 In its simplest form
of measurement, the optical fibers are
employed as waveguides to transport
light to and from a solution to be
analyzed, noting that total internal
reflection is the underlying mechanism.
One of the major advantages of using
optical biosensors in conjunction with
optical fibers is that it permits sample
analysis to be done over long distances
and this has important implications for
field monitoring. However, the main
drawback apart from being relatively
expensive is that optical fibers may
suffer from miniaturization problems.§§
Notwithstanding, the application of
optical fiber-based nanosensors has
become an area of significant interest
and various methods have been devel-
oped to alleviate the problems arising
from miniaturization.94
Surface plasmon resonance (SPR) is a
form of reflectance spectroscopy that has
been widely used in biosensor develop-
ment. It has been demonstrated that SPR
plays a significant role in relation to
immunogenicity, food analysis, proteo-
mics, drug discovery, and DNA analy-
sis.95–97 This method is particularly
attractive for direct label-free detection
and a number of papers have shown that
the SPR-based biosensor is a powerful
tool for EID monitoring. Studies by the
group of Andreu98–100 revealed that SPR
is a particularly useful tool for screening
the virus of foot-and-mouth disease
(FMD). It was used to study the effects
of combining multiple amino acid repla-
cements within the sequence of the
antigenic GH loop of FMD virus.100
The influence of amino acid substitutions
within A15 was also determined, and it
was shown that SPR can rapidly screen
antigens while simultaneously providing
kinetic data on the antigen–antibody
interaction.98 Validation studies revealed
that the results are in agreement with the
relative antigenicities as determined by
competition ELISA.98 By contrast,
Gomara et al.101 developed an SPR-
based immunosensor, which uses syn-
thetic peptides for the detection of the
hepatitis A virus in human serum. More
importantly, it is reported that the
sensitivity of SPR is comparable to
ELISA.101 Recently, Chen et al.102 used
a SPR biosensor to study the coronavirus
of severe acute respiratory syndrome
(SARS). It was shown that SPR was
able to verify that the N-terminal deleted
proteinase dimer adopts a state different
from that of the full-length proteinase
dimer.102
SPR is one of very few techniques that
are able to provide non-invasive, real-
time kinetic data on association and
dissociation rates, along with equilibrium
binding constants for receptor or ligand
systems."" Recently, Myszka and co-
workers103 demonstrated that it is possi-
ble to rapidly screen many antibodies
from hybridoma culture samples using
the same SPR sensor surface. This is an
important requirement when high sample
throughputs are needed such as establish-
ing the type of infection in a group of
sentinel animals. In fact, various workers
have shown that a portable hand-held
SPR-based biosensor (Spreeta2) can be
deployed for continuous monitoring of
toxins.104,105 However, some reports sug-
gest that the Spreeta2 technology is not
as sensitive as the standard ELISA
method.106 One of the challenges that
limit the application of SPR for real-time
measurements in blood is that the signal
is very sensitive to non-specific physical
binding on the surface.39 Careful engi-
neering of the surface may in some
cases minimize undesirable adsorption
processes; however, the long-term stabi-
lity of the surface layer is likely to fail
when in direct contact with blood. While
SPR is an interesting and appealing
transduction method, one must note that
the measuring range is very limited. It
appears that the technique struggles to
detect biochemical compounds or bio-
molecules, which have a molecular
weight of less than 5000 daltons. In spite
of these pitfalls, there seems to be a
general push to develop a hand-held SPR
device that can be used to directly detect
pathogens in the environment. The
development of a technology which can
be taken into the field and provide real
time monitoring is a step in the right
direction in tackling the proliferation of
EIDs.
Fluorescence measurements are of
particular interest in biosensor systems
due to their high sensitivity.26 In most
fluorescent-based immunoassays, fluoro-
chromes are used to label the biomole-
cules and generate the fluorescent signal,
noting that neither antigens nor antibo-
dies exhibit any fluorescence properties.
Recently, Walt and coworkers107
reviewed the impact of fluorescence-
based nucleic acid detection and micro-
arrays on the biological sciences.
Biosensor arrays employing fluores-
cence-based detection of biohazards
(i.e., viral, bacterial, toxins, etc.) have
undergone a revolution in terms of
miniaturization and automation.108 The
group of Ligler109,110 showed that a
fluorescence-based multianalyte immu-
nosensor array can be used to simulta-
neously detect various microorganisms
and toxins. Furthermore, it is reported
that the technology exhibits comparable
sensitivity to the standard ELISA
method.109 The biosensor consists of a
patterned array of biological recognition
elements (i.e., antibodies, receptors)
immobilized on the surface of a planar
waveguide, and a fluorescence assay is
performed on the patterned surface,
which yields an array of fluorescent
spots. Signal transduction is achieved
by using a diode laser for fluorescence
excitation and a CCD camera to capture
the image. Other workers have shown
that fluorescence is an amenable and
sensitive approach for the detection of
dengue virus. Renard et al.111 developed
a fluorescent-based immunosensor,
whereas the group of Baeumner112,113
§§ Unlike electrochemical-based transducers
that are concentration sensitive detectors and
therefore perform better when miniaturized
(i.e., microelectrodes), diminishing the sample
volume with mass sensitive optical biosensors
reduces the concomitant signal intensity or
sensitivity.
"" SPR has the advantage that it can measure
complex formation without labelling the
reactants, and it can analyse samples from
crude preparations.
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fabricated a nucleic acid microfluidic
biosensor that employs liposome signal
amplification, and showed that detection
down to the picomolar range can be
achieved. Despite the improved sensiti-
vity and reduced analysis time, further
developmental work still needs to be
performed in a complex sample such as
blood and serum, if these devices are to
be routinely used for the detection of
infectious diseases in the field. Another
drawback of fluorescence technology is
that it requires relatively expensive
reagents, and often gives rise to a
reaction that is time consuming.
Notwithstanding, the capability to per-
form real time measurements is an area
of significant interest for the detection of
EIDs.108
2.3 Piezoelectric biosensors
Piezoelectric detection works on the
principle that frequency variations of an
oscillating quartz crystal correspond to
changes in mass as a result of a
biochemical reaction/biorecognition
event (i.e., antibody–antigen interaction,
DNA hybridization).16,114 There are two
types of piezoelectric sensors which have
been used to detect EIDs: (a) bulk wave
or quartz crystal microbalance (QCM)
and (b) surface acoustic wave. Some
reports advocate that the surface acoustic
wave format is more sensitive compared
to bulk wave.16 Others have evaluated
the detection limit of various biosensor
platforms and concluded that the piezo-
electric method is inferior compared to
electrochemical and optical detectors.114
Notwithstanding, a number of articles
have recently appeared in the literature,
which use the piezoelectric sensor
approach to detect a wide range of
viruses. The group of Rickert115 reported
on a quartz crystal microbalance for
FMD virus. A synthetic peptide with
the amino acid sequence 135–154 of the
capsid protein VP-1 of FMD virus was
covalently linked to the gold surface via a
self-assembled monolayer of alkane thiol,
and the frequency change was followed
with time after exposure to antibody.115
Similarly, Gajendragad and coworkers116
developed a piezoelectric immunosensor
for FMD and reported a shelf life of
18 weeks after storing the antibody-
coated crystal at room temperature.
More importantly, it was demonstrated
that the biosensor can detect the FMD
virus in clinical samples, and the
results compared well with ELISA.116
By contrast, Zhou et al.117 successfully
used a piezoelectric-based DNA bio-
sensor for the detection of hepatitis B
virus. A nucleic acid probe was immo-
bilized onto the gold electrode via a
polyethyleneimine–glutaraldehyde cross-
linking process. Despite the sensor
responding linearly to hepatitis B over a
limited concentration range (i.e., 0.02–
0.14 mg ml21), it was demonstrated
that the crystal can be regenerated/
activated by exposing the surface to a
hydroxide and acid solution followed by
an ethanol wash.117 Zuo et al.118 fabri-
cated an immunosensor for severe acute
respiratory syndrome (SARS), and
detected a frequency shift that was
proportional to the antigen concentra-
tion in the range 0.6–4 mg ml21. The
piezoelectric crystal was coated with
horse polyclonal antibody induced by a
SARS-associated coronavirus, and the
detection of the antigen was achieved by
spraying it in the form of an aerosol via
ultrasonic oscillation.118 By contrast, the
groups of Tai and Wu119–121 used the
QCM biosensor to monitor dengue virus.
More importantly, Tai et al.120 used a 15-
mer peptide template and developed a
novel molecular imprinting approach to
fabricate their QCM biosensor. It was
demonstrated that molecular imprinting
may be a promising method for alleviat-
ing problems arising from non-specific
interactions.
The QCM transduction method is an
attractive option for real-time monitor-
ing of EIDs. It is apparent from the
aforementioned studies that most
workers have overcome many of the
challenges, which face this technique.
In addition, the sensitivity and reliability
of the piezoelectric biosensor is compar-
able to the conventional ELISA
method.122 Despite the promising analy-
tical performance of the piezoelectric
sensor further work still needs to be
undertaken to evaluate the stability of
the sensor surface in biological fluids.
Problems such as crystal regeneration,
relatively long incubation times, non-
specific binding of proteins or other
biomaterials, and loss of material coat-
ing after washing are well known limita-
tions of this technique,16,26,114 which
still require further attention before
this biosensor technology platform is
used routinely for EID detection.II
3 Biosensor outlook
Biosensors have become an integral
aspect of modern life, as they have
allowed us to monitor our environment
and surroundings, so that we can control
and manipulate it in a way that ensures
our survival. What does the future hold
for biosensors for the detection of EIDs?
Before we can answer this question, it is
important to ask what is the rate of
growth of activity involving biosensors?
The number of scientific publications
published and patents issued worldwide
each year gives a general guide of the
growth rate. Between 1984 and 1990,
there were approximately 300 scientific
publications and 227 patents on biosen-
sors. From 1991 to 1997, roughly
3000 articles were published and over
376 patents were filed. A survey of the
period 1998 to 2004 has revealed that
well over 6000 articles have been pub-
lished and about 1100 patents have been
issued and/or are pending. The number
of papers published and patents issued
per year is an important indicator of
research activity, and the present growth
rate suggests that the future looks very
bright indeed. Similarly, there are some
indications that biosensors may play an
important role in the biosecurity and/or
military sectors in the near future..15***
The future research outlook for EID
detection using biosensors looks positive,
despite reports suggesting that very little
market growth or progress has occurred
over the past few years.124
In spite of all the research, there is a
long way to go before biosensors can be
used to detect EIDs in real-time.
Biofouling of the sensor membrane is
still a major obstacle that has limited the
widespread application of biosensors.125
II Controlling the physical dimensions and
properties of the piezoelectric material is
another problem that also needs to be
addressed. Some reports suggest that each
crystal needs to be calibrated separately, since
its frequency depends on the crystal geometry
and the immobilization technique.123
*** Since September 11th, 2001, the detection
of biohazards in the environment has become
an issue of great concern.18 The war on
terrorism is driving the need for biosensors
to rapidly detect biowarfare agents, and a
great deal of research has been directed
towards this area.
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It has been shown that the accurate long-
term usage of implanted sensors is
dictated by fibrosis formation that devel-
ops around the sensor and subsequently
inhibits the influx of analyte to the
detector. If a biosensor is to be employed
for real-time monitoring of EIDs in
blood, serum or other biological fluids,
it must be able to withstand the rigours
of long-term exposure. A number of
methods have been developed to over-
come biofouling problems.126 None of
these approaches appear to completely
eliminate membrane biofouling,
although there are some promising signs
in prolonging sensor functionality.
Recent efforts have been directed
towards developing new ways of improv-
ing the biocompatibility of biosensors.
Wang et al.80 demonstrated that deposit-
ing heparin onto the surface of an
amperometric biosensor can significantly
improve sensor biocompatibility. Work
by Ward et al.127 has shown that
vascularization of the foreign body cap-
sule which surrounds a subcutaneous
biosensor improves the life of the sensor.
Polymers have also received a lot of
attention in relation to chemical modifi-
cation of electrode and sensor surfaces.
Brown and Lowry128 examined various
Nafion1 coating procedures, and
demonstrated that ascorbic and uric acid
interferences can be removed during
in vivo measurements in the brain.
Recently, Higson and coworkers129 have
shown that biosensors coated with poly-
(ethylene glycol)-calix[4]resorcinarenete-
trathiol may play an important role in
suppressing electrode biofouling and/or
passivation problems. By contrast,
Meyerhoff and coworkers130–133 have
tackled the biocompatibility problem by
incorporating nitric oxide (NO) releasing
polymers [i.e., polyurethane, poly(vinyl
chloride) and polydimethylsiloxane
doped with diazeniumdiolate functional
groups] within the sensor membrane that
prevent thrombogenesis. Despite exten-
sive research efforts, the use of biosen-
sors for real-time detection of EIDs
has not gained widespread clinical
acceptance.
Bioreceptor stability and activity are
an important criterion for the develop-
ment of a robust and a long-lasting
biosensor. Irrespective of the type of
biosensor, immobilization of the biore-
ceptor onto a solid support plays a major
role in determining the overall perfor-
mance of the device. For a biosensor to
be successful, it is somewhat necessary
that the bioreceptor remains attached
irreversibly to the transducer.{{{ While
self-assembled monolayers formed on
macroscopic gold surfaces have been
studied in depth,37,38,134 it is not known
if this approach generates a surface that
allows long-term measurements of EIDs.
However, recent work has shown that
enzymes can be attached to porous
silicon using an organic linker, and still
retain their biomolecular activity.135,136
Others have shown that scanning probe
nanolithography can be used in conjunc-
tion with chemoselective protein-to-
surface linkers to create templates for
fabricating virus arrays.137 If a biosensor
is to be developed for long-term, real-
time measurements of EID in a biologi-
cal fluid/environmental sample then the
surface of the sensor must be durable and
selective for the target analyte. Another
challenge facing immunosensors is that
they are not completely reversible, so
that only a single immunoassay can be
performed. This can be a pitfall for
applications that may require real-time
monitoring; however, a great deal of
effort has been directed towards the
development of renewable antibody sur-
faces103 and ‘reagentless’ or ‘label-free’
sensing.21,62
The literature contains a vast descrip-
tion of a wide range of biosensors that
exploit enzymes, nucleic acids, and anti-
bodies in conjunction with electro-
chemical, optical, and piezoelectric
transducers. An important trend in bio-
sensors is the development of miniaturized
devices such as the lab-on-a-chip.12{{{
Equally, the development of microscale
separation devices, particularly micro-
machined capillary electrophoresis (CE)
chips, has witnessed an explosive growth
in recent years.138 Such miniaturized
devices provide the capability to shrink
conventional ‘bench-top’ separation sys-
tems with major advantages of speed,
cost, portability, and solvent and/or
sample consumption. Subsequently, the
integration of micro-electrochemical sys-
tems for local detection, implantable or
portable devices, and measurement in
small volumes opens the way for applica-
tions in EID monitoring. Advancements
in nanotechnology will further assist with
the development of miniaturized and/or
hand-held biosensors. In fact, optical
fiber-based nanosensors depend on the
construction of nanometre-sized optical
fibers. Consequently, the application of
atomic force microscopy is becoming an
important research tool for characterizing
ligand-receptor interactions, and this
technique will certainly foster the devel-
opment of innovative nanosensors.
Similarly, the increasing growth of the
telecommunications industry will support
the development of new and improved
optical methods. In fact, fiber optic
sensors are beginning to generate intense
interest for in vivo monitoring, and this
paves the way for new and important
advances in real-time clinical monitoring
of EIDs.
The type of device selected will depend
on a number of issues such as: What is
the sensitivity and/or detection limit of
the biosensor? Although, many of the
biosensors described in this review can be
used to detect EIDs at very low levels,
the sensor sensitivity will also be system
dependent (i.e., the size, type, and
structure of the antigen) rather than just
transducer dependent. What is the cost?
Is the biosensor versatile? Is it preferred
to monitor continuously, or to collect
samples and periodically test them? If the
system stays in the field for weeks or
months, then maintaining the biological
component of the biosensor can be rather
difficult. In fact, most existing biosensors
(i.e., immunosensors, DNA biosensors)
cannot withstand the rigours of long-
term implantation. Another problem
that needs to be addressed is the biosen-
sor response time. There are relatively
few biosensors around that can accu-
rately assay a biological sample in less
than several minutes. Most devices
have an analysis time that range from
15 minutes to several hours. Clearly, a
biosensor device that is rapid, robust,
and durable will be highly desirable for
field applications. Very few of the bio-
sensors investigated in this review satisfy
the aforementioned criteria; however,
much more validation work still needs
to be done before they are accepted and
{{{ Immobilizing the bioreceptor onto selected
sites while still retaining the activity and the
binding power of the biological moiety is a
significant challenge in biosensor research.
{{{ Miniaturization saves large amounts of
expensive or rare biological material, and thus
lowers the development and production costs.
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embraced by the medical and/or scientific
community for real-time monitoring.
Detailed data and evaluation protocols
on performance characteristics of biosen-
sors, as well as comparisons with estab-
lished methods, are missing in most
cases.
4 Conclusions
There is no doubt that biosensors have
recently undergone significant improve-
ments in terms of their achievable selec-
tivity and detection limits. Although
there are many hand-held or field bio-
sensors available, most of these technol-
ogies have not been fully realized for the
detection of EIDs. The development of
biosensors for the detection of infectious
diseases is still in its infancy. Many
technical and/or scientific challenges still
exist irrespective of the type of biosensor
platform. It has been shown in this
review that the biosensor response
depends on many experimental factors
such as antigen/antibody loading, surface
preparation/immobilization conditions,
incubation time, temperature, type of
biological fluid, etc. These factors deter-
mine the success of a biosensor for a
particular EID and therefore need to be
carefully controlled/optimized if reliable
measurements are going to be made. In
addition, problems such as matrix inter-
ference, specific adsorption of blood
components onto the sensor surface and
drift are common for all biosensor
devices. Currently, most biosensors show
excellent results in pristine laboratory
samples; however, very few are suffi-
ciently robust to be employed directly for
the real-time detection of EID in biolo-
gical samples (i.e., blood). Similarly, a
majority of the biosensors developed for
EID detection have so far undergone
limited clinical evaluation, and further
work needs to be done before they make
their way into the market place. The key
issue that needs to be addressed in the
future is the increasing demand for
sensor biocompatibility that will allow
biomolecules to be monitored in real
time. A great deal of research has been
undertaken on the development of new
materials (i.e., carbon nanotubes, poly-
mers, etc.), which may overcome some of
the challenges and limitations facing
existing biosensor technologies.
Designers of biosensor devices need to
be aware of the specific needs for a
particular analytical device. It is a must
for the designer to look at the special
demands of clinical chemistry prior to
making new developments. The signifi-
cant technological advances made over
the past decade are certain to facilitate
the application of biosensors for the
detection of EIDs.
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